Phase 2 N=10 Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
Pharmacokinetics
Primary: Unbound Ceftolozane Exposure in the Plasma — 322.6 mg*h/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=46 Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates
Herpes Simplex
Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment (Motor Scores). — 10; 5; 0; 1 participants
N/A N=231 Lumbar Puncture and Syphilis Outcome
Syphilis
Primary: Appropriate Decline in Serum Rapid Plasma Reagin Test (RPR) Titer — 38; 30 Participants — p=0.29
N/A N=8 Cerebrospinal Fluid (CSF) Pharmacokinetics of Antimicrobials in Children
Infections
Primary: CSF:Serum Ratio of Vancomycin — 0.08 ratio
Phase 4 N=20 Temperature Control in Central Fever in the Neuro-ICU
Fever · Brain Hemorrhage
Primary: Core Temperature as Measured With an Approved Device (Urinary Catheter) in Place for Usual Clinical Care — 100.8; 100.3; 99.9; 99.5 degrees F
N/A N=198 Prevention of Neurosurgical Wound Infections
Surgical Wound Infections
Primary: Incidence of Infection That Requires Removal of the Neurosurgical Device — 97; 98 Participants
N/A N=214 Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Encephalitis · Meningitis
Primary: Total Number of Cases With at Least One Provider Response — 98; 58 cases
Phase 4 N=434 Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System
Intraventricular Hemorrhage · Subarachnoid Hemorrhage
Primary: Number of Infections — 4; 5; 4; 5 Infections
Phase 1 N=13 The Maraviroc Central Nervous System (CNS) Study
HIV Infections
Primary: CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS) — 1.01 ratio
Phase 2 N=40 High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement
B-cell Lymphomas
Primary: Event-free Survival — 16 Participants
Phase 2 N=6 Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Brain and Central Nervous System Tumors · Lymphoma
Primary: Number of Phase I Participants Experiencing Toxicity — 1; 3 Participants
Phase 2 N=219 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
N/A N=433 A Registry for Comparing Catheter-Related Infection Rates Among Various Shunt Systems in the Treatment of Hydrocephalus
Hydrocephalus
Primary: Number of Subjects With Shunt Infections — 14 participants
N/A N=18 Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
HIV Infections
Primary: Change in CSF Concentrations of Neopterin After 12 Weeks — 0.1; 0.3 nmol/L
Phase 2 N=168 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Cryptococcal Meningitis · HIV Infections
Primary: Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B — 14; 11; 11; 6 Participants — p=0.0012
Phase 2 N=91 Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Chemotherapeutic Agent Toxicity · Cognitive/Functional Effects · Lymphoma
Primary: Progression-free Survival — 2.1; NA years — p=0.015
Phase 3 N=1,103 Topical Vancomycin for Neurosurgery Wound Prophylaxis
Infection · Surgery · Nervous System Diseases
Primary: Any Surgical-site Infection as Evidenced by Surgeon or Attending Physician Diagnosis, or Signs and Symptoms of Infection Assessed by Phone Call Interview or at In-office…
Phase 1 N=13 PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
HIV Infections
Primary: Frequency of Grade 3 or Higher Adverse Events — 0 number of occurrences
N/A N=52 Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Lymphoma
Primary: Total Number of Participants Who Experienced Acute Treatment Related Adverse Events — 52 Participants
Phase 2 N=336 Indocyanine Green for Central Nervous System Tumors
Suspected Central Nervous System Tumors
Primary: Sensitivity (SBR) — 5.49 ratio
Phase 3 N=59 Clinical Trial of CNS-targeted HAART (CIT2)
HIV Infections
Primary: Neuropsychological Performance Change — -0.27; -0.17 units on a scale
Phase 2 N=378 Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth
HIV Infections · Meningitis
Primary: Number of Immunogenic Responders, With Response Defined as a 4-fold or Greater Increase in Serum Bactericidal Antibody Titers From Study Entry to Week 28 After 2 Doses…
Phase 3 N=333 Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
Complicated Urinary Tract Infection · Complicated Intra-abdominal Infection
Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant
Phase 3 N=15 Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals
HIV-1-infection
Primary: Total Doravirine Concentrations in Cerebrospinal Fluid — 58.6 ng/ml
Phase 2 N=75 New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
Diffuse Large B-cell Lymphoma
Primary: 1 Year Progression Free Survival (PFS) — 58 Percentage of participants
N/A N=81 To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection
Acute Hepatitis C · HIV · HIV Infections
Primary: Association of 11C-labelled PK11195 Uptake Using PET With Acute HCV and HIV Infection — 0.18; 0.22 binding potential ratio
Phase 2 N=78 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Brain and Central Nervous System Tumors · Intraocular Melanoma · Lung Cancer
Primary: Six-month Overall Survival — 67; 11 Participants
Phase 1 N=3 Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities
Phase 4 N=375 Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis
Bacterial Meningitis
Primary: Day 7 Mortality — 61; 64 Participants
N/A N=33 Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care
Antibiotic Resistant Infection · Infection
Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate